Wipawan Thangnipon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wipawan Thangnipon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Nirut Suwanna
Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University , Kamphaeng Saen , Nakhonpathom , 73140 , Thailand
6 shared publications- Nicha Puangmalai
Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, USA
4 shared publications Patoomratana Tuchinda
Department of Chemistry, Faculty of Science, Mahidol University, Bangkok, Thailand
4 shared publicationsRungtip Soi-Ampornkul
Department of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
4 shared publicationsSaksit Nobsathian
Nakhon Sawan Campus, Mahidol University, Phayuhakiri, Nakhon Sawan, Thailand
4 shared publicationsChanati Jantrachotechatchawan
Mahidol University
2 shared publications
Latest Publications
- Open Access
- 27 May 2021
- Published by Faculty of Medicine Siriraj Hospital, Mahidol University in Siriraj Medical Journal
- Vol. 73 (6) , 413-422
Protective Roles of N-trans-feruloyltyramine Against Scopolamine-Induced Cholinergic Dysfunction on Cortex and Hippocampus of Rat Brains
Objective: To study the protective effects of N-trans-feruloyltyramine (NTF) on scopolamine-induced cholinergic dysfunction, apoptosis, and inflammation in rat brains. Materials and Methods: Treatments were administered intraperitoneally (i.p.). Wistar rats (8-week-old) were allocated into 4 groups (n = 3) as follows: scopolamine-only, NTF-only, NTF + scopolamine and control. Spatial cognition was evaluated by Morris water maze. ROS assay and Western blot analyses were conducted in 3 brain regions: the frontal cortex, hippocampus, and temporal cortex. Results: NTF treatment inhibited scopolamine-induced memory impairment and significantly attenuated scopolamine-induced changes in the three brain regions. Investigated scopolamine-associated changes were as follows: increases in ROS production and BACE1 level, decrease in ChAT level, increases in inflammatory and apoptotic markers, and activation of signaling pathway kinases related to inflammation and apoptosis. Conclusion: With its in vivo antioxidant, cholinergic-promoting, anti-apoptosis, and anti-inflammatory biological activities, NTF is a promising candidate to be further investigated as a potential treatment for Alzheimer’s-associated neurodegeneration.
- 27 May 2021
- Published by Faculty of Medicine Siriraj Hospital, Mahidol University in Siriraj Medical Journal
- Vol. 73 (6) , 413-422
Open AccessProtective Roles of N-trans-feruloyltyramine Against Scopolamine-Induced Cholinergic Dysfunction on Cortex and Hippocampus of Rat Brains
Objective: To study the protective effects of N-trans-feruloyltyramine (NTF) on scopolamine-induced cholinergic dysfunction, apoptosis, and inflammation in rat brains. Materials and Methods: Treatments were administered intraperitoneally (i.p.). Wistar rats (8-week-old) were allocated into 4 groups (n = 3) as follows: scopolamine-only, NTF-only, NTF + scopolamine and control. Spatial cognition was evaluated by Morris water maze. ROS assay and Western blot analyses were conducted in 3 brain regions: the frontal cortex, hippocampus, and temporal cortex. Results: NTF treatment inhibited scopolamine-induced memory impairment and significantly attenuated scopolamine-induced changes in the three brain regions. Investigated scopolamine-associated changes were as follows: increases in ROS production and BACE1 level, decrease in ChAT level, increases in inflammatory and apoptotic markers, and activation of signaling pathway kinases related to inflammation and apoptosis. Conclusion: With its in vivo antioxidant, cholinergic-promoting, anti-apoptosis, and anti-inflammatory biological activities, NTF is a promising candidate to be further investigated as a potential treatment for Alzheimer’s-associated neurodegeneration.
- 14 January 2020
- Published by Springer Nature in Cytotechnology
- Vol. 72 (1) , 155-164
Neuroprotection of SAK3 on scopolamine-induced cholinergic dysfunction in human neuroblastoma SH-SY5Y cells
Alzheimer’s disease (AD) is the most common type of senile dementia. A number of factors have been proposed regarding pathology of AD, such as presence of β-amyloid, and cholinergic and oxidative stress. SAK3 (ethyl 8′-methyl-2′,5-dioxo-2-piperidin-1-ylspiro[cyclopentene-3,3′-imidazo[1,2-a]pyridine]-1-carboxylate) reduces β-amyloid deposition and improves cognitive functions in amyloid precursor protein knock-in mice. Scopolamine is used to induce in cell lines a cholinergic deficit that mimics AD. In order to evaluate the possible neuroprotective properties of SAK3, human neuroblastoma SH-SY5Y cells were pretreated with the compound (25–100 nM) and further incubated in the presence of scopolamine (2 mM). SAK3 inhibited scopolamine-induced cellular apoptosis (morphologically and by determination of pro- and anti-apoptotic factor levels), increase in ROS levels, decrease in choline acetyltransferase level, phosphorylation of NF-κB, activation of Akt, JNK and p38 intracellular signaling pathways, and elevation of proinflammatory cytokines IL-1β and IL-6, but not enhanced level of β-site amyloid precursor protein cleaving enzyme 1 (BACE1). These results indicate SAK3 possessed protective properties against cholinergic deficit associated with anti-oxidant, anti-apoptotic and anti-inflammatory activities, suggesting that SAK3 might be a potential agent in the development of AD drug therapeutics.
- 14 January 2020
- Published by Springer Nature in Cytotechnology
- Vol. 72 (1) , 155-164
Neuroprotection of SAK3 on scopolamine-induced cholinergic dysfunction in human neuroblastoma SH-SY5Y cells
Alzheimer’s disease (AD) is the most common type of senile dementia. A number of factors have been proposed regarding pathology of AD, such as presence of β-amyloid, and cholinergic and oxidative stress. SAK3 (ethyl 8′-methyl-2′,5-dioxo-2-piperidin-1-ylspiro[cyclopentene-3,3′-imidazo[1,2-a]pyridine]-1-carboxylate) reduces β-amyloid deposition and improves cognitive functions in amyloid precursor protein knock-in mice. Scopolamine is used to induce in cell lines a cholinergic deficit that mimics AD. In order to evaluate the possible neuroprotective properties of SAK3, human neuroblastoma SH-SY5Y cells were pretreated with the compound (25–100 nM) and further incubated in the presence of scopolamine (2 mM). SAK3 inhibited scopolamine-induced cellular apoptosis (morphologically and by determination of pro- and anti-apoptotic factor levels), increase in ROS levels, decrease in choline acetyltransferase level, phosphorylation of NF-κB, activation of Akt, JNK and p38 intracellular signaling pathways, and elevation of proinflammatory cytokines IL-1β and IL-6, but not enhanced level of β-site amyloid precursor protein cleaving enzyme 1 (BACE1). These results indicate SAK3 possessed protective properties against cholinergic deficit associated with anti-oxidant, anti-apoptotic and anti-inflammatory activities, suggesting that SAK3 might be a potential agent in the development of AD drug therapeutics.
- 9 September 2019
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 45 (1) , 44-51
Protective effects of diarylpropionitrile against hydrogen peroxide-induced damage in human neuroblastoma SH-SY5Y cells
Oxidative stress is implicated in pathogenesis of neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. The study demonstrates diarylpropionitrile (DPN), an antioxidant selective agonist of estrogen receptor β, protected human neuroblastoma SH-SY5Y cells against H2O2-induced toxicity by attenuating production of reactive oxygen species, apoptosis, autophagy, NF-κB activation, MAPK p38, JNK and ERK 1/2 signaling pathways, and β-site amyloid precursor protein cleaving enzyme level, but, interestingly, stimulating Akt pathway. These findings indicate the important potential of DPN to ameliorate oxidative stress-associated damage in neurodegenerative disorders.
- 9 September 2019
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 45 (1) , 44-51
Protective effects of diarylpropionitrile against hydrogen peroxide-induced damage in human neuroblastoma SH-SY5Y cells
Oxidative stress is implicated in pathogenesis of neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. The study demonstrates diarylpropionitrile (DPN), an antioxidant selective agonist of estrogen receptor β, protected human neuroblastoma SH-SY5Y cells against H2O2-induced toxicity by attenuating production of reactive oxygen species, apoptosis, autophagy, NF-κB activation, MAPK p38, JNK and ERK 1/2 signaling pathways, and β-site amyloid precursor protein cleaving enzyme level, but, interestingly, stimulating Akt pathway. These findings indicate the important potential of DPN to ameliorate oxidative stress-associated damage in neurodegenerative disorders.
- Open Access
- 1 January 2017
- Published by Medknow in Neural Regeneration Research
- Vol. 12 (9) , 1492-+
Neuroprotection of N-benzylcinnamide on scopolamine-induced cholinergic dysfunction in human SH-SY5Y neuroblastoma cells
Alzheimer's disease, a progressive neurodegenerative disease, affects learning and memory resulting from cholinergic dysfunction. Scopolamine has been employed to induce Alzheimer's disease-like pathology in vivo and in vitro through alteration of cholinergic system. N-benzylcinnamide (PT-3), purified from Piper submultinerve, has been shown to exhibit neuroprotective properties against amyloid-β-induced neuronal toxicity in rat cortical primary cell culture and to improve spatial learning and memory of aged rats through alleviating oxidative stress. We proposed a hypothesis that PT3 has a neuroprotective effect against scopolamine-induced cholinergic dysfunction. PT-3 (125–200 nM) pretreatment was performed in human neuroblastoma SH-SY5Y cell line following scopolamine induction. PT-3 (125–200 nM) inhibited scopolamine (2 mM)-induced generation of reactive oxygen species, cellular apoptosis, upregulation of acetylcholinesterase activity, downregulation of choline acetyltransferase level, and activation of p38 and JNK signalling pathways. These findings revealed the underlying mechanisms of scopolamine-induced Alzheimer's disease-like cellular dysfunctions, which provide evidence for developing drugs for the treatment of this debilitating disease.
- 1 January 2017
- Published by Medknow in Neural Regeneration Research
- Vol. 12 (9) , 1492-+
Open AccessNeuroprotection of N-benzylcinnamide on scopolamine-induced cholinergic dysfunction in human SH-SY5Y neuroblastoma cells
Alzheimer's disease, a progressive neurodegenerative disease, affects learning and memory resulting from cholinergic dysfunction. Scopolamine has been employed to induce Alzheimer's disease-like pathology in vivo and in vitro through alteration of cholinergic system. N-benzylcinnamide (PT-3), purified from Piper submultinerve, has been shown to exhibit neuroprotective properties against amyloid-β-induced neuronal toxicity in rat cortical primary cell culture and to improve spatial learning and memory of aged rats through alleviating oxidative stress. We proposed a hypothesis that PT3 has a neuroprotective effect against scopolamine-induced cholinergic dysfunction. PT-3 (125–200 nM) pretreatment was performed in human neuroblastoma SH-SY5Y cell line following scopolamine induction. PT-3 (125–200 nM) inhibited scopolamine (2 mM)-induced generation of reactive oxygen species, cellular apoptosis, upregulation of acetylcholinesterase activity, downregulation of choline acetyltransferase level, and activation of p38 and JNK signalling pathways. These findings revealed the underlying mechanisms of scopolamine-induced Alzheimer's disease-like cellular dysfunctions, which provide evidence for developing drugs for the treatment of this debilitating disease.
- 1 January 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 610, 6-12
Potential role of N-benzylcinnamide in inducing neuronal differentiation from human amniotic fluid mesenchymal stem cells
- 1 January 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 610, 6-12
Potential role of N-benzylcinnamide in inducing neuronal differentiation from human amniotic fluid mesenchymal stem cells
- Open Access
- 21 October 2015
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 14, 1135-1114
A genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy
Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer's disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.
- 21 October 2015
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 14, 1135-1114
Open AccessA genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy
Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer's disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.
- Open Access
- 4 June 2015
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 7 (1) , 1-18
Connectivity and circuitry in a dish versus in a brain
In order to understand and find therapeutic strategies for neurological disorders, disease models that recapitulate the connectivity and circuitry of patients’ brain are needed. Owing to many limitations of animal disease models, in vitro neuronal models using patient-derived stem cells are currently being developed. However, prior to employing neurons as a model in a dish, they need to be evaluated for their electrophysiological properties, including both passive and active membrane properties, dynamics of neurotransmitter release, and capacity to undergo synaptic plasticity. In this review, we survey recent attempts to study these issues in human induced pluripotent stem cell-derived neurons. Although progress has been made, there are still many hurdles to overcome before human induced pluripotent stem cell-derived neurons can fully recapitulate all of the above physiological properties of adult mature neurons. Moreover, proper integration of neurons into pre-existing circuitry still needs to be achieved. Nevertheless, in vitro neuronal stem cell-derived models hold great promise for clinical application in neurological diseases in the future.
- 4 June 2015
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 7 (1) , 1-18
Open AccessConnectivity and circuitry in a dish versus in a brain
In order to understand and find therapeutic strategies for neurological disorders, disease models that recapitulate the connectivity and circuitry of patients’ brain are needed. Owing to many limitations of animal disease models, in vitro neuronal models using patient-derived stem cells are currently being developed. However, prior to employing neurons as a model in a dish, they need to be evaluated for their electrophysiological properties, including both passive and active membrane properties, dynamics of neurotransmitter release, and capacity to undergo synaptic plasticity. In this review, we survey recent attempts to study these issues in human induced pluripotent stem cell-derived neurons. Although progress has been made, there are still many hurdles to overcome before human induced pluripotent stem cell-derived neurons can fully recapitulate all of the above physiological properties of adult mature neurons. Moreover, proper integration of neurons into pre-existing circuitry still needs to be achieved. Nevertheless, in vitro neuronal stem cell-derived models hold great promise for clinical application in neurological diseases in the future.
- 4 April 2015
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 38 (7) , 1380-1388
Protective roles of N-benzylcinnamide on cortex and hippocampus of aged rat brains
Brain aging has been associated with oxidative stress leading to inflammation and apoptosis. The protective effects and underlying mechanisms of N-benzylcinnamide (PT-3), purified from Piper submultinerve, on brains of 90-week-old Wistar rats were investigated following daily intraperitoneal injection with 1.5 mg of PT-3/kg of body weight for 15 days. PT-3 treatment improved spatial learning and memory of aged rats and caused significant changes in brain frontal cortex, hippocampus, and temporal cortex in parameters associated with oxidative stress (decreased reactive oxygen species production and iNOS and nNOS levels), inflammation (reduced levels of IL-1β and IL-6), apoptosis (reduced levels of Bax and activated caspase-3, and elevated level of Bcl-2), and signaling pathways related to inflammation and apoptosis (decreased amounts of phospho-JNK and -p38, increased phospho-Akt level and no change in phospho-ERK1/2 content) compared to controls. PT-3 treatment also inhibited aged rat brain AChE activity. These results suggest that PT-3 with its intrinsic antioxidant and AChE inhibitory properties has therapeutic potential in ameliorating, in part, age-associated damages to the brain.
- 4 April 2015
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 38 (7) , 1380-1388
Protective roles of N-benzylcinnamide on cortex and hippocampus of aged rat brains
Brain aging has been associated with oxidative stress leading to inflammation and apoptosis. The protective effects and underlying mechanisms of N-benzylcinnamide (PT-3), purified from Piper submultinerve, on brains of 90-week-old Wistar rats were investigated following daily intraperitoneal injection with 1.5 mg of PT-3/kg of body weight for 15 days. PT-3 treatment improved spatial learning and memory of aged rats and caused significant changes in brain frontal cortex, hippocampus, and temporal cortex in parameters associated with oxidative stress (decreased reactive oxygen species production and iNOS and nNOS levels), inflammation (reduced levels of IL-1β and IL-6), apoptosis (reduced levels of Bax and activated caspase-3, and elevated level of Bcl-2), and signaling pathways related to inflammation and apoptosis (decreased amounts of phospho-JNK and -p38, increased phospho-Akt level and no change in phospho-ERK1/2 content) compared to controls. PT-3 treatment also inhibited aged rat brain AChE activity. These results suggest that PT-3 with its intrinsic antioxidant and AChE inhibitory properties has therapeutic potential in ameliorating, in part, age-associated damages to the brain.
- 22 September 2014
- Vol. 13, 1097-103
Neuroprotection by diarylpropionitrile in mice with spinal cord injury.
The initial impact of spinal cord injury (SCI) often results in inflammation leading to irreversible damage with consequent loss of locomotor function. Minimal recovery is achieved once permanent damage has occurred. Using a mouse model of SCI we observed a transitory increase followed by a rapid decline in gene expression and protein levels of nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of cellular anti-oxidative genes. Immediate treatment with diarylpropionitrile (DPN), a non-steroidal selective estrogen receptor ß ligand, resulted in a significant increase in Nrf2 levels, and reduction of inflammation and apoptosis compared to untreated SCI animals. Furthermore, DPN-treatment improved locomotor function within 7 days after induction of SCI. DPN acted through activation of PI3K/ Akt pathway, known to be involved in down-regulation of apoptosis and up-regulation of cell survival in injured tissues. These findings suggest that immediate activation of cellular anti-oxidative stress mechanisms should provide protection against irreversible tissue damage and its profound detrimental effect on locomotor function associated with SCI.
- 22 September 2014
- Vol. 13, 1097-103
Neuroprotection by diarylpropionitrile in mice with spinal cord injury.
The initial impact of spinal cord injury (SCI) often results in inflammation leading to irreversible damage with consequent loss of locomotor function. Minimal recovery is achieved once permanent damage has occurred. Using a mouse model of SCI we observed a transitory increase followed by a rapid decline in gene expression and protein levels of nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of cellular anti-oxidative genes. Immediate treatment with diarylpropionitrile (DPN), a non-steroidal selective estrogen receptor ß ligand, resulted in a significant increase in Nrf2 levels, and reduction of inflammation and apoptosis compared to untreated SCI animals. Furthermore, DPN-treatment improved locomotor function within 7 days after induction of SCI. DPN acted through activation of PI3K/ Akt pathway, known to be involved in down-regulation of apoptosis and up-regulation of cell survival in injured tissues. These findings suggest that immediate activation of cellular anti-oxidative stress mechanisms should provide protection against irreversible tissue damage and its profound detrimental effect on locomotor function associated with SCI.
- 1 August 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 578, 44-49
Neuroprotective effects of diarylpropionitrile against β-amyloid peptide-induced neurotoxicity in rat cultured cortical neurons
- 1 August 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 578, 44-49
Neuroprotective effects of diarylpropionitrile against β-amyloid peptide-induced neurotoxicity in rat cultured cortical neurons